BL
ALXN

Balentine LLC’s Alexion Pharmaceuticals ALXN Stock Holding History

Balentine LLC’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-102
Closed -$11K – 926
2020
Q2 		$11K Buy
102
+29
+40% +$3.08K ﹤0.01% 546
2020
Q1 		$7K Sell
73
-285
-80% -$28K ﹤0.01% 441
2019
Q4 		$39K Buy
358
+327
+1,055% +$35K ﹤0.01% 226
2019
Q3 		$3K Buy
31
+24
+343% +$2.71K ﹤0.01% 626
2019
Q2 		$1K Buy
+7
New +$902 ﹤0.01% 752
2018
Q3 		– Sell
-70
Closed -$9K – 393
2018
Q2 		$9K Buy
+70
New +$8.18K ﹤0.01% 104
2018
Q1 		– Sell
-170
Closed -$20K – 573
2017
Q4 		$20K Sell
170
-3
-2% -$365 ﹤0.01% 383
2017
Q3 		$24K Sell
173
-48
-22% -$6.52K ﹤0.01% 370
2017
Q2 		$27K Buy
221
+90
+69% +$10.5K ﹤0.01% 332
2017
Q1 		$16K Hold
131
– – ﹤0.01% 379
2016
Q4 		$16K Sell
131
-36
-22% -$4.41K ﹤0.01% 356
2016
Q3 		$20K Buy
167
+36
+27% +$4.63K ﹤0.01% 280
2016
Q2 		$15K Buy
+131
New +$18.6K ﹤0.01% 285

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Balentine LLC's ALXN Position: Q3 2020 in Review

Balentine LLC sold out of Alexion Pharmaceuticals (ALXN) in Q3 2020, closing a stake of 102 shares — an estimated $11K sold.

Balentine LLC first reported a position in ALXN in Q2 2016 and held it in 13 quarters. The position peaked at $39K in Q4 2019. 709 funds tracked by Wall St. Rank hold ALXN as of Q3 2020.

  • Balentine LLC reported no remaining Alexion Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Balentine LLC sold 102 Alexion Pharmaceuticals shares in Q3 2020, an estimated $11K.
  • Balentine LLC first reported a position in Alexion Pharmaceuticals in Q2 2016 and held it in 13 quarters.
  • Balentine LLC's Alexion Pharmaceuticals position peaked at $39K in Q4 2019.
  • 709 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2020.

Based on Balentine LLC's 13F filing for Q3 2020, filed 2 Nov 2020.